Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INDOCO.NS
HoldPremium GrowerIndoco Remedies Limited · Healthcare · India · $237M · Avg Vol: $2M/d
57
StockRankGet insider-trade alerts
Q
54
V
39
M
59
P/E (TTM)
325.6x
ROE
-10.1%
D/E
1.2x
Dividend %
0.1%
COMPANY DESCRIPTION
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.4B | 17.9B | 16.4B | 17.9B | 3.0% | 18.7B | 19.7B | 22.5B | 11.9% |
| EPS (INR) | 15.44 | 10.68 | -8.00 | -10.31 | -30.8% | — | — | — | — |
| Shares | 92.2M | 92.2M | 92.2M | 92.2M | +0.0% | 92.2M | — | — | — |
| Debt | 3.3B | 6.7B | 9.9B | 10.9B | 48.5% | 10.9B | — | — | — |
| Equity | 10.3B | 11.1B | 10.2B | 9.4B | -3.0% | — | — | — | — |
| Op CF | 1.8B | 1.6B | 907.6M | 2.3B | 8.2% | 2.3B | — | — | — |
| Inv CF | -2.1B | -4.3B | -2.6B | -873.8M | — | — | — | — | — |
| Fin CF | 228.0M | 1.2B | 1.7B | -1.3B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+2.7%
SMA 50SMA 200
Close
$2.43
RSI (14)
55.6
52W High
$3.49
From 52W High
0.7%
SCORE BREAKDOWN
Quality
54
ROIC
8.6%66.6
ROE
-10.1%34.9
GP/Assets
50.5%86.6
Op. Margin
1.4%45.0
FCF/Assets
3.9%64.7
Piotroski
668.8
Int. Cover
1.1x39.2
D/E Ratio
1.17x11.5
Current Ratio
1.13x14.8
Value
39
P/E (TTM)
325.6x1.8
EV/EBITDA
19.7x35.6
P/FCF
22.4x60.0
P/B
2.1x61.5
P/S
1.1x81.4
Div Yield
0.1%1.5
Momentum
59
52W High %
70%48.6
RS 6M
22%81.5
SMA 50/200
1.07x70.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$237M
P/E (Forward)
19.0x
Gross Margin
69.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INDOCO.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INDOCO.NS | Indoco Remedies Limited(you) | $237M | 57 | Hold |
| AMRUTANJAN.NS | Amrutanjan Health Care Limited | $153M | 53 | Hold |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
| BAJAJHCARE.NS | Bajaj HealthCare Limited | $120M | 59 | Hold |
| THEMISMED.NS | Themis Medicare Limited | $129M | 62 | Hold |
| SHUKRAPHAR.NS | Shukra Pharmaceuticals Limited | $252M | 38 | Hold |
| HIKAL.NS | Hikal Limited | $320M | 75 | Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| BAFNAPH.NS | Bafna Pharmaceuticals Limited | $77M | 55 | Hold |
| GUJTHEM.NS | Gujarat Themis Biosyn Limited | $622M | 52 | Hold |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%